"These three-year data show that raising the bar in atopic dermatitis treatment to long-term total skin clearance was an achievable treatment goal for at least half of EBGLYSS Week 16 responders, ...

Amlitelimab is an investigational anti-OX40 ligand monoclonal antibody designed to normalize the overactive immune response in patients with atopic dermatitis.

The human monoclonal antibody known as tralokinumab-ldrm was tested and approved as a safe, effective treatment for pediatric patients with atopic dermatitis aged 12 to 17 years old. Originally ...

Please provide your email address to receive an email when new articles are posted on . Ebglyss is a targeted interleukin-13 inhibitor approved for the treatment of moderate-to-severe atopic ...

How do dermatologists diagnose atopic dermatitis? To diagnose atopic dermatitis, also called eczema, a board-certified dermatologist carefully examines your (or your child's) skin and asks questions. ...

Please provide your email address to receive an email when new articles are posted on . Pediatric patients treated with nemolizumab saw a statistically significant improvement in pruritus. Nemolizumab ...

(RTTNews) - Eli Lilly and Co. (LLY) announced that its Ebglyss monotherapy monthly injection demonstrated sustained and deep responses in patients with moderate-to-severe atopic dermatitis over three ...

Findings showed 21% of patients treated with tralokinumab achieved an IGA score of 0 or 1 at week 16 compared with 4% of those who received placebo. The Food and Drug Administration (FDA) has expanded ...

Atopic dermatitis involves complex immune and neuronal pathways, with biologics targeting IL-4, IL-13, and IL-31 showing promise in treatment. Diagnostic and treatment strategies must consider skin ...

MedPage Today brought together three expert leaders for a virtual roundtable discussion on atopic dermatitis: Moderator Peter Lio, MD, of Northwestern University Feinberg School of Medicine in Chicago ...